Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options
- PMID: 37893596
- PMCID: PMC10608066
- DOI: 10.3390/medicina59101878
Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options
Abstract
Elderly-onset rheumatoid arthritis (EORA) is a distinct clinical entity defined as the onset of rheumatoid arthritis (RA) in individuals aged over 60 years. EORA presents unique clinical features, including a more equitable distribution of sexes, a potential predilection for male involvement, a higher incidence of acute onset characterized by constitutional symptoms, a propensity for systemic manifestations, elevated sedimentation rates at disease onset, a reduced occurrence of rheumatoid factor positivity, increased titers of anti-citrullinated protein antibodies, a preference for involvement of large joints, elevated disease activity, the presence of bone erosions, and heightened patient disability. RA is recognized to consist of three partially overlapping subsets. One subset mirrors the classical RA clinical presentation, while the remaining subsets exhibit either a polymyalgia rheumatica-like phenotype or present with remitting seronegative symmetrical synovitis accompanied by pitting edema syndrome. In the initial stages of EORA management, non-steroidal anti-inflammatory drugs (NSAIDs) are not typically the first-line treatment choice, because seniors are much more prone to develop side effects due to NSAIDs, and the use of NSAIDs is in reality contraindicated to the majority of seniors due to comorbidities. Disease-modifying antirheumatic drugs (DMARDs), frequently methotrexate, are introduced immediately after the diagnosis is made. In cases where elderly patients demonstrate resistance to conventional DMARD therapy, the introduction of biological or targeted synthetic DMARDs becomes a viable treatment option. EORA presents a unique clinical profile, necessitating tailored treatment strategies. Our study emphasizes the challenges of NSAID use in seniors, highlighting the imperative shift toward DMARDs such as methotrexate. Future research should explore personalized DMARD approaches based on disease activity, comorbidities, and safety considerations, aiming to optimize treatment outcomes and minimize glucocorticoid reliance, thereby enhancing the quality of care for EORA patients.
Keywords: elderly-onset rheumatoid arthritis; prognosis; rheumatoid arthritis; treatment.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Treatment strategies for elderly-onset rheumatoid arthritis in the new era.Mod Rheumatol. 2022 Apr 18;32(3):493-499. doi: 10.1093/mr/roab087. Mod Rheumatol. 2022. PMID: 34791359 Review.
-
Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort.Int J Rheum Dis. 2019 Jun;22(6):1084-1093. doi: 10.1111/1756-185X.13428. Epub 2018 Nov 11. Int J Rheum Dis. 2019. PMID: 30415498
-
Management issues with elderly-onset rheumatoid arthritis: an update.Drugs Aging. 2005;22(10):809-22. doi: 10.2165/00002512-200522100-00002. Drugs Aging. 2005. PMID: 16245956 Review.
-
Elderly-onset rheumatoid arthritis.Semin Arthritis Rheum. 1994 Jun;23(6):367-78. doi: 10.1016/0049-0172(94)90087-6. Semin Arthritis Rheum. 1994. PMID: 7939723 Review.
-
Rheumatoid arthritis in the elderly. Prevalence and optimal management.Drugs Aging. 1995 Jul;7(1):30-7. doi: 10.2165/00002512-199507010-00004. Drugs Aging. 1995. PMID: 7579779 Review.
Cited by
-
Multiple Ulcers in the Ileum and Lymphadenopathy Following the Usage of Methotrexate in a Patient With Rheumatoid Arthritis: A Case Report.Cureus. 2024 Feb 1;16(2):e53406. doi: 10.7759/cureus.53406. eCollection 2024 Feb. Cureus. 2024. PMID: 38435188 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical